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Objective: To study the association of CT perfusion imaging parameters with plasma
level of transforming growth factor-b1 (TGF-b1) and vascular endothelial growth
(VEGF) in patients with non small cell lung cancer (NSCLC).
Methods: A total of 67 patients with NSCLC (NSCLC group) and 64 patients with
benign lesion (control group) were given with CT perfusion imaging to obtain blood ﬂow,
blood volume, mean transit time, time to peal and permeability surface through CT
perfusion software. The plasma levels of TGF-b1 and VEGF were tested by ELISA. The
relationship between plasma levels of TGF-b1, VEGF and CT perfusion imaging pa-
rameters were analyzed.
Results: CT perfusion imaging parameters and the plasma levels of TGF-b1 and VEGF
of NSCLC group were signiﬁcantly higher than the control group (P < 0.05), while CT
perfusion parameters and the levels of TGF-b1 and VEGF in NSCLC group showed
signiﬁcant difference in different tumor node metastasis stages (P < 0.05). Correlation
analysis showed that the level of plasma TGF-b1 and VEGF were positively correlated
with blood ﬂow, blood volume, and mean transit time (P < 0.05), and negatively
correlated with time to peal (P < 0.05). There was no signiﬁcant correlation between
TGF-b1 and VEGF with the permeability surface.
Conclusions: CT perfusion imaging parameters in patients with NSCLC is closely
associated with plasma TGF-b1, VEGF and its biological characteristics. CT perfusion
imaging is a convenient method to detect tumor blood perfusion.1. Introduction
Nowadays, the morbidity and mortality of lung cancer is
increasing year by year. Eighty percentage of patients with lung
cancer have non small cell lung cancer (NSCLC) [1].
Angiopoiesis affects the occurrence and development of
tumor. It can slow down growth and can terminate metastasis
if angiopoiesis of new vessels is blocked. Transforming
growth factor-b (TGF-b1) and vascular endothelial growth
(VEGF) play important roles in regulation of angiopoiesis [2].
Multi-slice spiral computed tomography perfusion imaging is a
mature functional imaging, and has been widely used in
observing density and distribution of tumor vessels, evaluating
association with tumor metastasis related genes. In this study, we
observed CT perfusion imaging parameters, including bloodﬂow (BF), blood volume (BV), mean transit time (MTT), time to
peal (TTP) and permeability surface (PS), analyzed the rela-
tionship between these parameters with TGF-b1 and VEGF, to
discuss the valued of these parameter in evaluating NSCLC.
2. Materials and methods
2.1. Objective
A total of 67 cases diagnosed as NSCLC by puncture or post-
operation pathological diagnosis were selected as NSCLC
group, who were admitted during January 2010 to January 2015.
Another 64 cases with benign lesion were selected as control
group. There were 40 males and 27 females in NSCLC group,
aged 33–78 years old, with average age as (50.8 ± 10.5) years.
There were 36 cases with squamous carcinoma, 23 cases with
adenocarcinoma, and 8 cases with adenoid squamous cell car-
cinoma. Among 64 cases in control group, there were 37 cases
with tuberculosis focus, 13 cases with pulmonary inﬂammatory
pseudotumor, 9 cases with silicosis nodule, and 5 cases withe under the CC BY-NC-ND license (http://
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t Value P value
BF 61.51 ± 12.23 36.65 ± 8.51 13.445 0.000
BV 11.15 ± 2.37 7.02 ± 1.25 12.390 0.000
MTT 8.69 ± 2.03 6.87 ± 1.35 6.013 0.000
TTP 20.45 ± 4.17 16.75 ± 3.51 5.511 0.000
PS 18.38 ± 5.15 14.39 ± 4.89 4.543 0.000
Table 2





t Value P value
TGF-b1 647.29 ± 71.27 443.32 ± 55.31 18.240 0.000
VEGF 187.23 ± 31.20 110.52 ± 28.24 14.731 0.000
Table 3
Parameters, TGF-b1 and VEGF levels of NSCLC patients at different
stage.
Indexes Group 1 (n = 23) Group 2 (n = 27) Group 3 (n = 17)
* *
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comparable in both groups.
2.2. Inclusion and exclusion criteria
Inclusion criteria: ①Patients were diagnosed as NSCLC by
bronchoﬁbroscopy biopsy, needle biopsy or post-operation
pathological diagnosis, and had no chemoradiotherapy or anti-
tumor drug; ②Patients were able to have CT perfusion
scanning.
Exclusion criteria: ①Sensitive to iodinated contrast agent;
②Breath-holding time were shorter than 25 s, or artifact
appeared due to various reasons; ③Patients with serious
dysfunction of heart, liver or kidney, or with infection diseases;
④Patients were diagnosed as small cell lung cancer by patho-
logical examination.
2.3. CT perfusion imaging
Patients underwent CT plain scanning to identify lesion
location. With the maximum lay of tumor as the center, dynamic
scanning was performed in multi-level continuous dynamic
movie scan model. The condition was as follows: 120 kV,
50 mA, detector width was 24 mm × 1.2 mm; coverage area of
Z-axis was 40 mm; thickness of reconstruction was 5 mm;
average interval time was 1.0 s; rescanned 5 s later; 320 pieces
of imagings were obtained after continuous collection for 40 s.
Patlak method and maximum-slope method were used to
calculate parameters, including BF, BV, MTT, TTP, PS, etc.
2.4. Collection and detection of blood
2.4.1. Collection of blood
Five mL elbow venous blood were extracted at 8:00 am for
fasting subjects in both groups. Anti-freezing was carried out
immediately with ethylenediaminetetraacetic acid. It was cen-
trifugated at 3600 r/min for 10 min. Supernatant was obtained
by pipettor, and preserved at −80 C.
2.4.2. Detection of TGF-b1 and VEGF
Enzyme linked immunosorbent assay was used to detect
content of TGF-b1 and VEGF. The assays were provided by
Aikang Biotechnology Company (Hangzhou, China). The pro-
cess was in accord with instruction. Two holes were detected for
every sample, and the average was calculated.
2.5. Statistical analysis
The data was processed by SPSS19.0. t Test was used in
comparison between groups. Pearson correlation analysis was
used to analyze the correlation between parameters with TGF-b1
and VEGF.BF 58.23 ± 10.62 65.42 ± 12.11 63.17 ± 12.23
BV 7.42 ± 3.02 11.49 ± 3.56* 12.82 ± 3.58*
MTT 7.04 ± 2.54 9.90 ± 3.47* 10.12 ± 3.51*
TTP 16.75 ± 3.85 21.85 ± 4.68* 22.32 ± 5.05*
PS 14.83 ± 4.62 19.57 ± 5.72* 21.18 ± 5.65*
TGF-b1 532.10 ± 45.33 696.39 ± 64.28* 688.91 ± 60.24*
VEGF 142.53 ± 15.73 202.54 ± 22.47* 197.56 ± 21.72*
BF: mL$100 mL−1$min−1; BV: mL/1000 mL; MTT: s; TTP: s; PS:
mL$100 mL−1$min−1; TGF-b1: pg/mL; VEGF: pg/mL. Compared with
group 1, *P < 0.05.3. Results
3.1. Parameters of two groups
Table 1 showed BF (mL$100 mL−1$min−1), BV (mL/
1000 mL), MTT (s), TTP (s) and PS (mL$100 mL−1$min−1)
were signiﬁcantly higher in NSCLC group (P < 0.05).3.2. TGF-b1 and VEGF levels
Table 2 showed that TGF-b1 and VEGF levels of NSCLC
group were signiﬁcantly higher than those of control group
(P < 0.01).
3.3. Parameters, TGF-b1 and VEGF levels of NSCLC
patients at different stage
All 67 NSCLC patients were divided into IA–IIA stage group
(n = 23, Group 1), IIB–IIIA stage group (n = 27, Group 2), IIIB–
IV stage group (n = 17, Group 3) according to clinical and CT
examination result. CT perfusion parameters, TGF-b1 and
VEGF levels were observed. There were signiﬁcant differences
in parameters, TGF-b1 and VEGF levels between group 1 and
group 2 (P < 0.05), and the differences were also signiﬁcant
between group 1 and group 3 (P < 0.05). However, the differ-
ence was not signiﬁcant between group 2 and group 3 (P > 0.05)
(Table 3).
3.4. Correlation between parameter with TGF-b1 and
VEGF
Pearson linear correlation analysis showed that the level of
plasma TGF-b1 and VEGF were positively correlated with BF,
BV, and MTT (P < 0.05), and negatively correlated with TTP
(P < 0.05). There was no signiﬁcant correlation between TGF-
b1 and VEGF with the PS (Table 4).
Table 4
Correlation between parameter with TGF-b1 and VEGF.
Parameters TGF-b1 VEGF
g P g P
BF 0.57 0.000 0.69 0.001
BV 0.48 0.000 0.56 0.000
MTT 0.31 0.019 0.45 0.004
TTP −0.53 0.015 −0.62 0.012
PS 0.54 0.220 0.78 0.091
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NSCLC is the commonest type of lung tumors. The
complicated biological processes such as occurrence, develop-
ment, metastasis etc are associated with angiopoiesis. Angio-
poiesis of tumor vessels includes angiopoiesis induced by tumor
cells and intra-tumor microcirculation, which is achieved by
angiopoiesis and vasculogenesis. Vasculogenesis refers to dif-
ferentiation of mesoblastema into haemangioblast, which is
predecessor of endothelial cell, and constitute embryo primitive
vascular system. In this stage, the growth of tumor is slow, and
shows no invasiveness, with few metastases [3]. Angiopoiesis
refers to growth of existed capillary or of new capillary in
postcapillary venule. It can obtain various nutritions for
growth, and is liable to inﬁltration and metastasis. Therefore,
it is easy for tumor to growth in area with rich new vessels
and sufﬁcient blood supply [4].
TGF-b super family-mediated signal path can regulate the
occurrence, development, metastasis of tumors. It can stimulate
the growth of vessels. There are three types of TGF-b for
mammal animals, and the content of TGF-b1 is the highest.
TGF-b1 is representative. It can stimulate vessel growth directly
or indirectly, which may be correlated with angiopoiesis and
development [5]. It is reported that malignant tumor cells can
secret plenty of cytokines during tumor development, which
lead to rapid proliferation of malignant tumor, and higher
expression of TGF-b1 [6]. Besides, VEGF is a glycoprotein
with many functions. It can stimulate proliferation and
migration of vascular endothelial cell. And it is also the
strongest vascular permeability agent. It can lead to
pathological angiopoiesis, including increasing mitosis and
migration of vascular endothelial cell [7,8].
CT perfusion imaging is a non-invasive method to evaluate
growth of microvessels in tumor tissues, then to reﬂect physio-
logical and metabolic changes via detecting various parameters.
Besides, it can also indicate clinical change characters of tumors
before any change in size occurs or just when tiny change oc-
curs. Tacelli et al. found that APA detected by dynamic contrast-
enhance spiral CT is positively correlated with VEGF expression
of adenocarcinoma. BF, BV, MTT, TTP and PS can reﬂect
microcirculation characters from various aspects [9]. This study
showed that the level of plasma TGF-b1 and VEGF were
positively correlated with BF, BV, and MTT, and negatively
correlated with TTP. It indicates that TGF-b1 and VEGF
expressions are increased, new vessels are increased and
circulation is also increased. From macroscopic aspect, CT
imaging is characterized as increased blood ﬂow in per unit
volume of tumor tissue per unit time (BF), increased bloodvolume in per unit volume of tumor tissue (BV), and delayed
time for contrast agent passing tissue capillary [10]. However,
PS which indicates permeability surface and integrity of
capillary, shows no signiﬁcant correlation with TGF-b1 or
VEGF. Tumor node metastasis staging reﬂects tumor progress
degree. The higher the stage is, the severer the progress is, the
wider the affected tissue. This progress is closely correlated
with angiopoiesis. Our study showed the difference in
parameters between IIB–IIIA and IIIB–IV is more signiﬁcant
than IA–IIA. This trend is consistent with TGF-b1 and VEGF
levels in plasma. It indicates that CT perfusion imaging not
only can be used in diagnosis and differentiation of benign
and malignant tumors, but also can be used in NSCLC staging
and prognosis.
In conclusion, a plenty of angiogenesis occurs during tumor
development. It can lead to increased TGF-b1 and VEGF levels.
CT perfusion imaging can reﬂect density and structure of
microvascular system from imaging aspect. The combination of
both is valuable in diagnosis, differentiation, treatment and
prognosis.
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